PARP1 OVEREXPRESSION

CI-VAR-00003033Explore in graph →CIViC 2586

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm1
PARP1 OVEREXPRESSION	Olaparib	Predictive	D	Supports Resistance	3	submitted	EID7867 Researchers compared biomarkers in breast cancer stem cell (BCSC) enriched and mature cancer cell populations from human breast cancer cell lines. Overexpression of PARP1 was found in BCSC enriched p… (full text at CIViC) PMID 25144364 · Gilabert et al., 2014 · Open in CIViC	civic
Malignant Peripheral Nerve Sheath Tumor1
PARP1 OVEREXPRESSION	Olaparib	Predictive	D	Supports Sensitivity Response	3	accepted	EID7016 The majority of MPNST samples were positive for PARP staining. Overall, moderate to high expression of PARP1 and PARP2 was observed (Table 1)....Overall, treatment continued for 60 d at which point 5 … (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Sarcoma1
PARP1 OVEREXPRESSION	Olaparib + TrabectedinCombination	Predictive	D	Supports Sensitivity Response	4	submitted	EID7868 Study of combination of trabectedin + olaparib in sarcoma cell lines and xenograft models. Initial results found combination therapy significantly reduced colony growth (p<0.001) in high-PARP1-expres… (full text at CIViC) PMID 28454547 · Pignochino et al., 2017 · Open in CIViC	civic